Marshall Wace
CNTX icon

Marshall Wace’s Context Therapeutics CNTX Stock Holding History

Marshall Wace’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
384,528
-2,563,913
-87% -$5.2M ﹤0.01% 2821
2026
Q1 		$7.72M Buy
2,948,441
+355,243
+14% +$830K 0.01% 1091
2025
Q4 		$3.81M Buy
2,593,198
+2,557,448
+7,154% +$2.99M ﹤0.01% 1277
2025
Q3 		$34.7K Buy
+35,750
New +$29K ﹤0.01% 2750
2025
Q1 		– Sell
-203,286
Closed -$213K – 2686
2024
Q4 		$213K Buy
+203,286
New +$352K ﹤0.01% 2333

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace's CNTX Position: Q2 2026 in Review

Marshall Wace reduced its Context Therapeutics (CNTX) stake by 87% in Q2 2026, selling an estimated $5.2M and leaving 384,528 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2821.

Marshall Wace first reported a position in CNTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $7.72M in Q1 2026. 59 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Marshall Wace held 384,528 shares of Context Therapeutics worth $211K as of Q2 2026.
  • Marshall Wace sold 2,563,913 Context Therapeutics shares in Q2 2026, an estimated $5.2M.
  • Context Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2821 holding.
  • Marshall Wace first reported a position in Context Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Marshall Wace's Context Therapeutics position peaked at $7.72M in Q1 2026.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.